Aduro Biotech, Inc. (NASDAQ:ADRO) has received an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $21.20.
ADRO has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Aduro Biotech in a research report on Wednesday, September 27th. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. William Blair reiterated an “outperform” rating on shares of Aduro Biotech in a research report on Monday, October 2nd. Zacks Investment Research upgraded Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, July 4th. Finally, Cowen and Company started coverage on Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating on the stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2017/11/13/aduro-biotech-inc-adro-receives-21-20-consensus-target-price-from-brokerages.html.
In related news, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $12.19, for a total transaction of $487,600.00. Following the transaction, the chief executive officer now directly owns 144,025 shares in the company, valued at $1,755,664.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Gregory W. Schafer sold 25,811 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $12.17, for a total value of $314,119.87. Following the transaction, the chief operating officer now owns 133,879 shares in the company, valued at $1,629,307.43. The disclosure for this sale can be found here. Insiders have sold 342,745 shares of company stock worth $3,956,397 over the last quarter. 6.60% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Aduro Biotech in the 3rd quarter worth about $127,000. Tudor Investment Corp ET AL raised its holdings in shares of Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,984 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 2,119 shares during the period. Finally, Voya Investment Management LLC raised its holdings in shares of Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 2,515 shares during the period. Hedge funds and other institutional investors own 35.05% of the company’s stock.
Aduro Biotech (ADRO) traded up 0.61% on Wednesday, hitting $8.30. The stock had a trading volume of 464,129 shares. The stock’s market cap is $619.28 million. Aduro Biotech has a one year low of $8.05 and a one year high of $15.52. The stock’s 50 day moving average is $10.25 and its 200 day moving average is $10.84.
Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $3.98 million. During the same quarter in the prior year, the company earned $0.03 earnings per share. The firm’s revenue was down 84.9% compared to the same quarter last year. Analysts anticipate that Aduro Biotech will post ($1.35) earnings per share for the current year.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.